Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Interaction Study of RV521 (Sisunatovir)
NCT03782662Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of sisunatovir in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration (Cmax) of Midazolam at Day 17, Area Under the Curve (AUC) of Midazolam at Day 17 and 6 more. Started Nov 2018; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03782662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782662.